Chronic levodopa (L-dopa) treatment of Parkinson's disease (PD) patients is sooner or later associated with the onset of motor complications, for example wearing off and dyskinesia. PD patients with motor complications usually require the addition of further PD drugs to reduce these L-dopa side effects and enhance its efficacy. Entacapone is an available catechol-O-methyltransferase (COMT) inhibitor, which was extensively investigated as add-on to L-dopa/dopadecarboxylase inhibitor (DDCI) application in PD patients. Safinamide, a watersoluble, orally active a-aminoamide derivative, which modulates dopaminergic and glutamatergic neurotransmission with a unique dual mechanism of action, has been studied in two placebo-controlled clinical trials as add-on therapy to L-dopa in fluctuating PD patients.
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The signs and symptoms of Parkinson's disease (PD), a chronic neurodegenerative disorder predominantly characterised by the loss of dopaminergic neurons in the substantia nigra pars compacta, are most effectively treated by levodopa (L-dopa). However, nearly all PD patients experience a fluctuating response to L-dopa sooner or later within the first 5 years of therapy dependent on dosing of L-dopa.
End-of-dose wearing off and dykinesias are the most common motor complications associated with L-dopa treatment. [1] [2] [3] Once they appear, the management of motor complications is often challenging and patients require recurrent drug therapy adjustments to improve fluctuations of movement without exacerbating severe dyskinesia. extends on time without troublesome dyskinesia. [5] [6] [7] Entacapone is a
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EuroPEan nEurological rEviEw potent and specific peripherally acting catechol-O-methyltransferase (COMT) with a nitro-catechol structure. 8 It is used as an adjunct to L-dopa/dopadecarboxylase inhibitor (DDCI) therapy and slows the peripheral degradation of L-dopa only (has no anti-parkinsonian activity on its own). There are no head-to-head clinical trials comparing safinamide and entacapone under clinical conditions as an add-on therapy to L-dopa.
The aim of the present analysis is a comparison of entacapone and safinamide as add-on treatments to L-dopa in fluctuating PD patients;
therefore, a meta-analysis of all the pertinent double-blind, placebocontrolled studies was performed to determine effect sizes of safinamide and entacapone.
Methods

Search Strategy
The complete sets of data on placebo-controlled efficacy trials with safinamide as add-on to L-dopa were provided by Zambon, which is currently developing this still investigational compound. These comprise all completed, randomised, double-blind, placebo-controlled studies in PD patients with motor fluctuations, already treated with stable L-dopa dose and who may be receiving further anti-parkinsonian drugs (study 016, NCT01187966, labelled SAF1 7 and SETTLE, NCT00627640, labelled SAF2 9, 10, 11 ). The duration of the trials was 24 weeks each.
A systematic search of the literature up to the end of September 2014 was performed on the MEDLINE and EMBASE databases using 
Study Selection
Eligible studies for the search were defined as any prospective, randomised, placebo-controlled and double-blinded trials (24 weeks/6 months' duration) on the efficacy and safety of entacapone in PD patients already receiving L-dopa (usually commercial formulations of L-dopa in a fixed combination with a DDCI), i.e. L-dopa+carbidopa, L-dopa+benserazide, with motor fluctuations. All other aspects of planned treatment were to be the same in both arms. Therefore, the following types of studies were not considered:
• Studies in healthy subjects or subjects in early-stage PD, without motor fluctuations;
• Switch studies (investigating the introduction of entacapone as add-on to L-dopa or L-dopa+DDCI), or any studies with a fixed L-dopa+DDCI+entacapone combination compared with the separate drug formulations, without parallel entacapone placebo treatment groups;
• Crossover studies -since focus was given to studies of sufficient duration to be comparable to the studies investigating safinamide;
• Studies not investigating efficacy and safety of entacapone, or entacapone and other treatments (for example, studies regarding physiology parameters, magnetic resonance imaging or pharmacokinetic parameters); and
• Studies of COMT inhibitors (COMTIs)-genotype interaction, which selected patients based on COMT gene polymorphism.
Study Appraisal and Methods
If different doses and/or dose ranges were found in the selected studies, these were to be analysed both as separate studies and collectively.
Among the analysed efficacy parameters were changes from baseline in daily L-dopa dose, total daily off time, total and percent on time and Unified Parkinson's Disease Rating Scale (UPDRS) scores (part I, II and III only).
Safety was analysed mainly on binary criteria (incidence of treatmentemergent adverse events [AEs], AEs plus deaths, discontinuation from the trials and the incidence of some specific AEs). Only parameters that had been evaluated and documented for both treatments were to be included in the analyses.
The effects within studies are quantified by changes from baseline in quantitative parameters or incidences of events (non-completers, discontinuations, incidences of treatment-emergent AEs). Fixed-effect and random-effects meta-analyses are used to provide effect sizes within each treatment group and to compare both groups. Fixed-effects methods aim at estimating unknown but constant effect sizes based on the assumption that the (retrieved) studies estimate a common (fixed)
effect. Random-effect methods consider the (retrieved) collection of studies as one possible random sample of a larger population, and aim at estimating the mean of a possible distribution of effect sizes.
The statistical analyses were carried out by means of Comprehensive Meta-Analysis Version 2 (CMA2) (Biostat, Englewood, NJ, US). Trial design, inclusion and exclusion criteria, blinding and randomisation of the selected trials were compared with regard to possible risk of bias. The following summary measures were used:
• Hedges' g, which is a measure of effect size 13 (as standardised mean difference);
• Odds ratios (ORs) (as a measure of association of binary data); and
• Risk differences (as a measure of difference between binary data).
The heterogeneity across studies was quantified by the I 2 -index, i.e. the ratio in percent of the true heterogeneity (the between-study variance)
to the total observed variance.
Results
Study Selection
The synthesis of results was based on four studies with entacapone, and the two safinamide studies. Initially, 30 publications (published from 1996 to 2012) concerning entacapone, describing a total of 13 distinct randomised, double-blinded and placebo-controlled clinical trials, were considered. For the period up to 2008 these results matched with the findings of Stowe et al. 12 Eventually, four entacapone studies were included for the meta-analysis (see Table 1 ). The four studies are 17 This last trial 17 recruited both fluctuating and non-fluctuating patients, but separate study results on the fluctuating patients were available; therefore, only those parts of the study results were included, whenever available (see Table 1 ). The main reason for exclusion of some studies was the short duration, which did not allow appropriate comparison with the safinamide studies.
All included entacapone studies considered a placebo-controlled administration of 200 mg oral dose with each dose of L-dopa. Metaanalyses were performed with all four studies whenever possible (or with only ENT1, 14,15 ENT2 14 and ENT3, 16 whenever outcomes for the subgroup of fluctuating PD patients were not documented in the available publications).
One of the safinamide trials (SAF1) had two dose arms (low dose and high dose, 50 mg/day and 100 mg/day, respectively), which were analysed as two separate studies (SAF1A, SAF1B, each compared with placebo) and additionally as a combined placebo-controlled dose group (SAF1C).
The other safinamide trial (SAF2) had only one dose arm (50-100 mg/ day), which was ascribed to high dose (hence labelled SAF2B) since after week 2 of the study period a large majority of the patients (224/274) had a dose of 100 mg/day for the rest of the study. Therefore, meta-analyses for safinamide trials are performed: (a) using all safinamide doses (SAF1A, SAF1B, SAF2B); (b) using combined safinamide doses (SAF1C, SAF2B);
and (c) using the high safinamide dose (SAF1B, SAF2B) only (see Table 2 ).
The safinamide studies included 1,218 patients in total and the entacapone studies 849 patients. No relevant differences were detected in terms of trial design, inclusion and exclusion criteria, blinding and randomisation of the selected trials.
Efficacy Endpoints
There was a greater decrease from baseline in the daily oral L-dopa dose observed with entacapone treatment compared with treatment with safinamide all doses (p<0.05; Figure 1 and Tables 3 and 4 ). This was also seen with the safinamide combined dose data, and with the random effects analyses. No significant differences between entacapone and safinamide treatment were observed in terms of total daily off time, total daily on time and percentage of on time ( Figure 1 and Tables 3 and 4 ). This was found with safinamide all doses, with safinamide-combined doses and with the fixed-and random-effect analyses. Similarly, no statistically significant differences appeared between safinamide and entacapone treatment with respect to changes from baseline in the UPDRS total score using all safinamide doses. The alternative analysis where the two active treatment arms (low and high dose) have been combined revealed similar results to the main analysis (see Figure 1 ).
Safety Endpoints
Some AEs regarded as candidates for the indirect comparison of entacapone and safinamide were not considered in this report because they were not reported in the entacapone studies (anxiety, confusion and agitation, depression, dry mouth, orthostatic hypotension and syncope) or because they were reported only in entacapone trials (ataxia and forgetfulness). The analysis of the number of discontinuations due to AEs and deaths was performed after exclusion of the study ENT4 by
Brooks et al., 17 because premature discontinuations in this study were not stratified by fluctuating and non-fluctuating patients.
There were no differences on study discontinuations due to AEs and deaths between safinamide and entacapone (p=0.2564), even if the number of discontinuations due to AEs occurred more frequently with entacapone treatment (OR 1.777; p=0.0464) than with safinamide EuroPEan nEurological rEviEw (OR 1.167; p=0.5037) (Figure 2 and Tables 3 and 4) . No changes in comparison with placebo were observed with safinamide treatment in terms of the number of non-completers, whereas this number was increased slightly with entacapone treatment.
A statistically significant difference in favour of safinamide was determined in the ORs versus placebo of total incidences of treatment-emergent AEs (p=0.0020) (see Tables 3 and 4 ). The funnel plot corresponding to the total incidences of treatment-emergent AEs identifies the trial by Poewe et al. 14 as an outlier among the trials with respect to the total AE incidences (see Figure 3A) . No heterogeneities were detected within both groups of studies however. The funnel plot generated with the alternative analysis where the two safinamide dose groups were combined confirms the result (see Figure 3B ).
The risk differences of the events/symptoms versus placebo are described in Figures 4 and 5. Significant differences in favour of safinamide were seen particularly in terms of nausea (p=0.002), vomiting (p=0.007), shortness 
Figure 1: Forest Plot Presentation of Meta-analyses Using All Safinamide Doses and Combined Safinamide Doses for the Following Efficacy Endpoints (A) Changes in the daily oral L-dopa dose; (B) changes from baseline in total daily off time; (C) changes from baseline in total daily on time; (D) changes from baseline in percentage on time; (E): changes from baseline in the total
Discussion
The number of trials included in this analysis is low. However, the 
